Galderma successfully placed an inaugural EUR 500 million single tranche Eurobond and new dual tranche CHF 435 million CHF bonds
Summary
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION.Zug, Switzerland, March 14, 2025 Galderma (SIX: GALD) has made significant progress on its refinancing strategy to spread out its maturity profile, diversify funding sources and reduce its interest costs, by successfully issuing the following bonds:The payment dates are March 20, 2025, for the Eurobond and the CHF bonds. The EUR transaction was led by BNP Paribas, J.P. Morgan, Mizuho, and Santander as active bookrunners, while the CHF transaction was led by UBS and BNP Paribas.Galderma is rated BBB (stable outlook) by Fitch and Fitch is expected to rate the bonds BBB.The net proceeds of the transactions will be used for the partial refinancing of Galdermas existing Bank Term Loan issued at its initial public offering (IPO) as well as for general corporate purposes. These successful issuances are leverage-neutral and do not materially affect Galdermas guidance for the full year 2025 on net financial expenses, last communicated on March 6, 2025, as part of the additional modelling metrics provided.Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. Since our foundation in 1981, we have dedicated our focus and passion to the human bodys largest organ the skin meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.